Orakl Oncology
PrivateLast Round
Series A
Nov 12, 2026
Total Funding Raised
$48.7M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Orakl Oncology operates in Healthcare & Life Sciences and is based in Villejuif. Its latest recorded funding round was a Series A round in November 2026.
Orakl Oncology is a biotechnology company that develops an AI-driven platform using patient-derived tumor avatars to accelerate cancer drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Orakl Oncology Comparables
Compare Orakl Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DeepLife | 86% | |
| TwinEdge Bioscience | 84% | |
| Cytocast | 84% |
For institutional investors. Book with your work email.
Orakl Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 12, 2026 | ||||
| Seed | Dec 3, 2024 | ||||
| Pre Seed | Oct 4, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Orakl Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Verve Ventures | Seed, Pre Seed, Series A |
| Plug and Play Tech Center | Series A |
| Singular | Seed, Series A |
| InfraVia Capital Partners | Series A |
| Speedinvest | Seed, Series A, Pre Seed |
| HCVC | Seed, Pre Seed, Series A |
| Teampact Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2026
$34M round led by Norrsken VC and Singular.
- Sep 1, 2026
Grew 19% QoQ, from 32 to 38 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 12, 2026
Orakl Oncology receives $34M in Series A funding led by Norrsken VC and Singular in France on Nov 12th '26.
For institutional investors. Book with your work email.
Orakl Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Orakl Oncology's valuation, stock price, and market status.
Is Orakl Oncology a public or private company?
Orakl Oncology is a private company.
What is the current stock price of Orakl Oncology?
Orakl Oncology is a private company, so its shares have no public market price. Caplight tracks Orakl Oncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Orakl Oncology worth (valuation)?
Valuation information for Orakl Oncology is not publicly available.
Can I buy Orakl Oncology stock?
Orakl Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Orakl Oncology's last funding round?
Orakl Oncology's most recent funding round was Series A on November 12, 2026.
Who are the main investors in Orakl Oncology?
Key investors in Orakl Oncology include Singular, Speedinvest, Norrsken VC.
Will Orakl Oncology IPO soon?
No public IPO plans have been announced for Orakl Oncology.
How can I track Orakl Oncology secondary market activity?
Caplight tracks bids, offers, and trades in Orakl Oncology's shares on secondary markets.